Frederic Bihel was born in 1976 in France. Funded by a government fellowship (MENRT), he earned a Ph.D. degree in organic chemistry in 2002 in the laboratory of Professor Jean-Louis Kraus (Marseille, France). Involved in a Alzherimer’s disease program in collaboration with Trophos (start up located in Marseille), he notably contributed to report the first protease inhibitor able to prevent gamma-secretase-mediated production of Ab40/42 without affecting Notch cleavage. Funded by both “Fondation pour la Recherche Médicale” and “France Alzheimer” fellowships, he spent one year and a half of postdoctoral studies at Harvard Medical School in the laboratory of Professor Michael S. Wolfe (Boston, Mass, USA). Dealing with solid phase peptide synthesis, he reported the discovery of subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase, intramembrane protease involved in Alzheimer’s disease. After training in biochemistry, he was involved in a biochemical program using photoaffinity probes, providing strong evidences of the presence of an initial substrate-binding site of gamma-secretase on presenilin, near the active site. In 2004, he moved to Strasbourg (France) where he joined the medicinal chemistry laboratory of Dr. Jean-Jacques Bourguignon as a Postdoctoral Researcher, before getting a permanent position as Associate Researcher of CNRS in 2005. His research interests deal with discovery, design, and development of new pharmacological tools and therapeutic agents targeting enzymes or receptors (GPCRs) for the treatment of specific diseases or dysfunctions of central nervous system (e.g. pain, inflammation, and psychiatric diseases). From a chemical point of view, his interest is focused on heterocyclic chemistry, synthesis of new heterocyclic scaffold, innovation in cross-coupling reaction, cycloisomerisation, and others.
Biography Updated on 17 April 2011